Search

Lisocabtagene maraleucel

[L43322] In 2025, the FDA also approved lisocabtagene maraleucel as the first CAR T-cell therapy in the United States for adult patients with relapsed or refractory marginal zone lymphoma (MZL). … [A228493] Despite the adverse reactions, the majority of patients given lisocabtagene maraleucel reported an overall increase in quality of life over a 1 year period.

Aprepitant

Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting … Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors.

Manidipine

Manidipine (INN) is a calcium channel blocker (dihydropyridine type) that is used clinically as an antihypertensive. … It is selective for vasculature and does not produce effects on the heart at clinically relevant dosages.

Droxidopa

Droxidopa is a precursor of noradrenaline that is used in the treatment of Parkinsonism. It is approved for use in Japan and is currently in trials in the U.S. … Though L-DOPS has been used in Japan and Southeast Asia already for some time, it is also currently in clinical trials at the phase III point in the United States (U.S.), Canada, Australia, and throughout

Fluticasone

[DB00588] was first approved in 1990[L5962] and [DB08906] was approved in 2007[L5965]. … Fluticasone is a synthetic glucocorticoid available as 2 esters, [DB08906] and [DB00588][F4355,F4358,F4361,F4364][FDA Label].

Lefamulin

[A183206] Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August 2019. … A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus.

p-Phenylenediamine

Levomethadone

Colfosceril palmitate

Colfosceril palmitate is a synthetic pulmonary surfactant administered in infants with respiratory distress syndrome. … [A31510] It was part of the first generation of commercially available artificial surfactants.[T70] It was developed by Burroughs Wellcome and it was FDA approved on August 6, 1990.

Rotavirus vaccine

[Label] Rotavirus vaccines are 90% effective in protecting against severe rotavirus infection.[L1117] … Rotateq is a live vaccine consisting of 5 reassorted human-bovine viral strains.[L1116] Rotarix is a live attenuated vaccine containing the 89-12 human strain.